Osaka, Japan –August 15, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for six compounds with 13 strengths of generic drugs. Among the six compounds, four compounds, Mirtazapine, Atomoxetine Hydrochloride, Tramadol Hydrochloride / Acetaminophen and Capecitabine, are approved for the first ... Read More
Maple Grove, MN – August 2, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has added another product to its growing generic portfolio, supporting its commitment to expanding and diversifying its product offerings. ... Read More
Offers Patients and Physicians a Fully Substitutable Generic Alternative with Brand-Quality Support
Vigadrone™ (vigabatrin) for Oral Solution, 500 mg. Upsher-Smith Laboratories, LLC
Maple Grove, MN – July 16, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch ... Read More
Learn More About Qudexy®XR’s Savings and Support Program at Booth #313
Maple Grove, MN – June 27, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be featuring Platinum Pass, the latest addition to ... Read More
RECOGNIZED FOR ITS INTERNAL COMMUNICATIONS PLAN FOR SAWAIStevie® Award Presentation to Upsher-Smith Left to right: Daina Basile (Kovak-Likly Communications), Elizabeth Likly (Kovak-LiklyCommunications), Jennifer Colvin (Upsher-Smith), Carol Weeklund (Upsher-Smith)
PHARMACEUTICALS’ACQUISITION OF UPSHER-SMITH LABORATORIES
Maple Grove, MN – June ... Read More
Osaka, Japan – June 20, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced that it has completed the transfer of manufacturing and marketing approval of Zomig® Tablets ... Read More
Osaka, Japan –June 14, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of seven compounds with 17 strengths of generic drugs. Sawai’s product line now ... Read More
Osaka, Japan –June 6, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OSELTAMIVIR Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI]*.
This approval expands the indication of OSELTAMIVIR Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI] to include the ... Read More